Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

Recruiting in Palo Alto (17 mi)

+28 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Pfizer

Trial Summary

What is the purpose of this trial?

This is a study to evaluate the safety of multiple doses of AAB-003 (PF-05236812) in patients with mild to moderate Alzheimer's Disease. Patients will receive either AAB-003 (PF-05236812) or placebo. Each patient's participation will last approximately 41 weeks.

Eligibility Criteria

Inclusion Criteria

Diagnosis of probable Alzheimer's Disease with MMSE score of 16-26, and brain MRI consistent with the diagnosis of Alzheimer's Disease

Concurrent use of cholinesterase inhibitor or memantine allowed, if stable.

Caregiver will participate and be able to attend clinic visits with patient

Treatment Details

Interventions

• AAB-003 (PF-05236812) (Monoclonal Antibodies)
• Placebo (Other)

Participant Groups

Group I: 8 mg/kg AAB-003 Experimental Treatment 1 Intervention

Group II: 4 mg/kg AAB-003 Experimental Treatment 1 Intervention

Group III: 2 mg/kg AAB-003 Experimental Treatment 1 Intervention

Group IV: 1 mg/kg AAB-003 Experimental Treatment 1 Intervention

Group V: 0.5 mg/kg AAB-003 Experimental Treatment 1 Intervention

Group VI: Placebo Placebo Group 1 Intervention

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

Borgess Medical Center Kalamazoo, MI

Borgess Research Institute Kalamazoo, MI

Brentwood Behavioral Healthcare Flowood, MS

Marty's Pharmacy Flowood, MS

More Trial Locations

Who Is Running the Clinical Trial?

Pfizer Lead Sponsor

JANSSEN Alzheimer Immunotherapy Research & Development, LLC Industry Sponsor

References